Аналитики считают Intuitive Surgical более выгодной инвестицией, чем Pressure BioSciences

Pressure BioSciences (OTCMKTS:PBIO – Get Free Report) and Intuitive Surgical (NASDAQ:ISRG – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations. Earnings & Valuation This table compares Pressure BioSciences and Intuitive Surgical”s revenue, earnings per share and valuation. Analyst Recommendations This is a summary of current ratings and price targets for Pressure BioSciences and Intuitive Surgical, as provided by MarketBeat. Intuitive Surgical has a consensus price target of $508.68, suggesting a potential upside of 28.94%. Given Intuitive Surgical’s stronger consensus rating and higher probable upside, analysts plainly believe Intuitive Surgical is more favorable than Pressure BioSciences. Profitability This table compares Pressure BioSciences and Intuitive Surgical’s net margins, return on equity and return on assets. Risk and Volatility Pressure BioSciences has a beta of 5.8, suggesting that its share price is 480% more volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Insider and Institutional Ownership 0.0% of Pressure BioSciences shares are owned by institutional investors. Comparatively, 83.6% of Intuitive Surgical shares are owned by institutional investors. 10.8% of Pressure BioSciences shares are owned by company insiders. Comparatively, 0.6% of Intuitive Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Summary Intuitive Surgical beats Pressure BioSciences on 12 of the 14 factors compared between the two stocks. About Pressure BioSciences Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts. About Intuitive Surgical Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California. Receive News & Ratings for Pressure BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pressure BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.